特考韦瑞(Tecovirimat) - 药物靶点：env_在研适应症：牛痘病毒感染，牛痘，猴痘_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Arestvyr、Tecovirimat Hydrate、Tecovirimat monohydrate

+ [8]

靶点

env

作用方式

抑制剂

作用机制

env抑制剂(重组包膜蛋白抑制剂)

治疗领域

感染

在研适应症

牛痘病毒感染牛痘猴痘+ [1]

非在研适应症

莫吉隆斯病正痘病毒感染

原研机构

SIGA Technologies, Inc.

在研机构

SIGA Technologies, Inc.

University of California, Davis

Japan Biotechno Pharma Co.,Ltd

非在研机构-

权益机构

Kalivir Immunotherapeutics, Inc.

SIGA Technologies, Inc.

Meridian Medical Technologies LLC

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2018-07-13),

天花

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C19H15F3N2O3

InChIKeyCSKDFZIMJXRJGH-VWLPUNTISA-N

CAS号869572-92-9

关联

23

项与特考韦瑞相关的临床试验

JPRN-jRCTs031240110

/ Suspended临床2期IIT

Evaluation of Treatment Safety and Efficacy in Hospitalized Patients with Mpox or Smallpox: A Multi-Institutional Collaborative Platform. sub-protocol01 Tecovirimat

开始日期2024-11-01

申办/合作机构-

NCT06156566

/ Recruiting临床4期IIT

European Randomised Clinical Trial on mPOX Infection

The goal of this randomized controlled double-blind clinical trial is to test the drug tecovirimat in patients with mpox (previously known as monkeypox) disease.
The main questions it aims to answer are:
* Is tecovirimat effective in treating mpox infection.
* Is tecovirimat safe to treat patients with mpox infection.
Participants will receive either the drug tecovirimat orally, 600 mg twice per day, or a matching placebo. The outcome of the infection and the side effect experienced will be compared between the two groups.

开始日期2024-08-09

申办/合作机构

University of Antwerp

[+1]

NCT06721585

/ Active, not recruitingN/AIIT

A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease - Extension Amendment

The purpose of the PALM007 extension is to further characterize the clinical and natural history of mpox, and to provide standard of care (SOC) during the ongoing outbreaks.

开始日期2024-07-10

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与特考韦瑞相关的临床结果

登录后查看更多信息

100 项与特考韦瑞相关的转化医学

登录后查看更多信息

100 项与特考韦瑞相关的专利（医药）

登录后查看更多信息

515

项与特考韦瑞相关的文献（医药）

2025-12-31·Virulence

Mpox: Global epidemic situation and countermeasures

Review

作者: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

2025-12-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Recent advances and perspectives in therapeutics for mpox

Review

作者: Yuan, Tao ; Zhang, Yaru ; Ma, Tingnan ; Su, Lingyu ; Zhong, Lei ; Yu, Dongke

Mpox, a viral illness caused by the monkeypox virus (MPXV), has gained global attention due to its outbreaks worldwide in recent years. MPXV infections pose significant public health threats with notable transmission risks, yet specific antiviral treatments remain limited. Current therapeutic approaches primarily rely on smallpox vaccines and a limited number of broad-spectrum antiviral agents, such as tecovirimat, lacking specific drugs against MPXV. Thus, it remains a significant clinical need to develop anti-MPXV agents for the prevention and control of mpox outbreaks. In this review, we summarized the characteristics of MPXV in terms of viral structure, genome, and replication while reporting the recent progress in the development of small molecule anti-MPXV agents. Additionally, we discussed major obstacles in anti-MPXV drug development, including insufficient understanding of virus biology, the lack of reliable disease models, and limited resources for conducting large-scale clinical evaluations, and provided insights and perspectives for anti-MPXV therapies, with the aims of accelerating the development of effective treatments and contributing to preparedness against emerging orthopoxvirus threats.

2025-09-01·ANTIVIRAL RESEARCH

Functional characteristics of plitidepsin as an antiviral treatment against monkeypox virus infection

Article

作者: Albericio, Guillermo ; Avilés, Pablo ; Guillén-Navarro, María J ; Cuevas, Carmen ; Sánchez-Cordón, Pedro J ; Flores, Sara ; García-Arriaza, Juan ; Noriega, María A ; Pérez, Patricia ; Rodríguez-Martín, Daniel ; Esteban, Mariano ; Astorgano, David

Monkeypox virus (MPXV), closely related to variola virus, causes mpox, a zoonotic disease traditionally endemic to Central Africa. However, recent outbreaks have increased human transmission of MPXV clades. In 2022, global MPXV spread was linked to clade IIb, whereas in 2024, the more pathogenic clade Ib became predominant. These trends raised concerns about sustained human transmission, prompting the WHO to declare mpox a Public Health Emergency of International Concern. Despite the availability of smallpox vaccines, their protective efficacy against mpox remains limited. Additionally, the limited efficacy of current smallpox antivirals, such as Tecovirimat and Brincidofovir, alongside growing concerns about the emergency of tecovirimat resistance mutants, underscores the need for new therapeutic options. Given these challenges, novel antiviral strategies with different mechanisms of action are urgently needed to control MPXV outbreaks. Plitidepsin, a cyclodepsipeptide drug initially approved for cancer treatment, has demonstrated potent antiviral activity against multiple viruses by targeting eukaryotic elongation factor 1 alpha (eEF1A). Here, we have evaluated the antiviral activity of plitidepsin against MPXV infection. In cultured cells, plitidepsin exhibited strong antiviral effects, with a favorable therapeutic index and low cytotoxicity. In CAST/EiJ mice, a highly susceptible MPXV model, plitidepsin significantly reduced viral replication in the lungs. Additionally, treated mice displayed a marked reduction in inflammatory lung lesions and proinflammatory cytokines, suggesting immunomodulatory effects. These findings indicate plitidepsin as a promising candidate for mpox treatment. Further studies are needed to explore its potential as a standalone or combination therapy, supporting clinical evaluation for mpox treatment.

172

项与特考韦瑞相关的新闻（医药）

2025-07-28

·GlobeNewswire-Health Care

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovationGAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease. “We believe in the importance of assessing brincidofovir, an antiviral, for this public health threat and we look forward to advancing our research across mpox as it’s a global disease of increasing concern,” said Simon Lowry, M.D., chief medical officer and head of research and development at Emergent. Mpox, formerly known as monkeypox, continues to pose a significant public health challenge, with ongoing regional and global outbreaks particularly in Central and West Africa. On August 14, 2024, the World Health Organization (WHO) declared the current mpox outbreak a global Public Health Emergency of International Concern (PHEIC).2 This marks the second mpox PHEIC declared by the WHO in the past two years, which followed the regional emergency declaration by the Africa Centres for Disease Control and Prevention (Africa CDC) on August 13, 2024.3 This month, the U.S. Centers for Disease Control and Prevention issued an updated report on the surge of mpox around the world.4 As part of the ongoing effort to identify safe and effective treatments for mpox, brincidofovir is currently being evaluated by the Africa CDC in partnership with PANTHER (PANdemic preparedness plaTform for Health and Emerging infectious Response) in the MpOx Study in Africa (MOSA), a double-blind, placebo-controlled clinical trial for people diagnosed with mpox, which initiated in January 2025. The study has received initial funding from Horizon Europe and Africa CDC. Dr. Lowry continued, “In addition to our engagement with PANTHER on the MOSA trial, this scientific review provides insights into the investigational use of brincidofovir in the treatment of mpox, and we are pleased this publication is available for the broader medical community.” Please see full Prescribing Information for TEMBEXA® (brincidofovir) for additional safety information.About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Safe Harbor StatementWe generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com __________________________ 1 https://doi.org/10.1080/14787210.2025.25320292 https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern3 https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent/ 4 https://www.cdc.gov/mpox/situation-summary/index.html

临床研究

2025-06-18

·普利制药

【招商】安徽普利钆布醇原料药获中国上市许可，并收到美国FDA正式批准信！

【招商】安徽普利钆布醇原料药获中国上市许可，并收到美国FDA正式批准信！海南普利制药股份有限公司（以下简称“普利制药”）控股子公司安徽普利药业有限公司（以下简称“安徽普利”）已于近日分别收到国家药品监督管理局(以下简称“NMPA”）签发的钆布醇化学原料药上市申请批准通知书和美国食品药品监督管理局（FDA）签发的钆布醇原料药正式批准信。此前，钆布醇原料药已获得欧盟CEP认证，并且在美国DMF注册随钆布醇注射液制剂获得FDA上市许可而自动转A，此次收到了FDA签发的正式批准信。随着本次国内上市申请获批(状态: A ; 已批准在上市制剂使用），标志着安徽普利钆布醇原料药已获得全球众多市场的准入资格，具备商业化生产能力，可持续稳定供应全球客户。1钆布醇原料药已获得全球81%市场的准入资格钆布醇是一种兼具高浓度和高弛豫率的大环状非离子型钆对比剂，显影更清晰，并且集合了对比增强成像的有效性和安全性，适用于全身全年龄段（包括足月新生儿）检查，包括肾功能不全患者。根据IMS数据显示，2024年全球钆布醇原料消耗量达38271KG，其中，美国（32%）、波兰（13%）、土耳其（11%）、中国（9%）、德国（5%）是钆布醇原料消耗量前5国家。至此，安徽普利钆布醇原料药已获得中国、美国、土耳其、欧盟等占全球份额约81%市场的准入和销售资格。数据来源：IMS安徽普利钆布醇原料药在中美欧等市场的原料药备案/登记情况：①US DMF号为039149（状态：A ；已收到正式批准信）;②CN登记号为Y20240000083，(状态: A ；已批准在上市制剂使用）；③CEP证书号：CEP 2024-082- Rev 00；④获得WC证明，获得土耳其市场的入场资格。安徽普利将利用自身产品优势，发挥国际注册的能力（已经在多国注册，并且有丰富的国际注册经验），借助国际化制造、质量控制体系和成熟的国际化市场开拓能力，愿与有志于开拓此产品的国内、国际制剂客户提供全方位、深度合作，共创未来。Welcome for enquiry, cooperation！联系人：Faye Xue电话：13616530509邮箱：ff@hnpoly.com2关于安徽普利安徽普利药业有限公司坐落于安庆国家高新技术产业开发区。是一家活性原料专业供应商，向全球医药、保健和护肤领域提供化学合成、生物合成的高品质特色原料。安徽普利目前拥有3个符合欧美中GMP标准的API 生产车间、10条生产线，357台多功能设备。依托强大的研发能力和技术转化能力，已完成造影剂（钆特酸葡胺、钆特醇、钆布醇、碘美普尔、碘普罗胺、碘佛醇、碘帕醇、碘克沙醇等）、合成生物学（司美格鲁肽、熊去氧胆酸、依克多因、红景天苷等）、抗肿瘤（BPA、环磷酰胺等）、其他原料药（盐酸多巴酚丁胺、硝普钠、氢氧化镁、阿普斯特、克立硼罗、伏立康唑、格隆溴铵、盐酸美金刚、特考韦瑞、阿昔洛韦钠、更昔洛韦钠、布美他尼、氟康唑、二硫化硒、别嘌醇等）、其他药用辅料（DOTA、SNAC、磺丁基-β-环糊精钠、卡特利多钙、考布曲钙钠等）等系列产品的研发与生产。3CPHI Shanghai 2025 诚邀莅临洽谈2025年世界制药原料上海展会CPHI Shanghai将于2025年6月24-26日在上海举办，是全球举办的医药原料系列展览之一。普利制药将在展会上展示国际原辅料制剂品种；欧美cGMP的全剂型CMO/CDMO服务；海南特殊政策的境外产品引进，代工服务；普利丰富的国际研发，注册和销售经验的国际化服务。普利制药将携其产品参展（展位号：W1E26），诚邀各方朋友莅临我司展位洽谈、指导！

上市批准医药出海

2025-04-08

·GlobeNewswire-Health Care

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents the fourth straight year of a special cash dividend. The amount of the dividend declared is consistent with the level of the dividend declared in March 2024. The dividend is payable on May 15, 2025, to shareholders of record at the close of business on April 29, 2025. “Today’s announcement of a special cash dividend reflects the strength of our balance sheet and continued confidence in the future of our business,” said Diem Nguyen, Chief Executive Officer. “As we look ahead, we remain committed to disciplined financial management and strategic execution to drive long-term shareholder value.” ABOUT SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com. FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,” “target,” “goal,” “potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that SIGA may not complete performance under the 75A50118C00019 BARDA Contract (the “BARDA Contract”) on schedule or in accordance with contractual terms, (ii) the risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled at the request or requirement of, or SIGA is not able to enter into new contracts to supply TPOXX to, the U.S. Government, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, including tariffs, on SIGA’s businesses, (xiii) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xiv) risks associated with actions or uncertainties surrounding the debt ceiling, and (xv) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2024 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Contacts:Suzanne Harnettsharnett@siga.com and InvestorsJennifer Drew-Bear, Edison GroupJdrew-bear@edisongroup.comMediaHolly Stevens, CG Lifehstevens@cglife.com

100 项与特考韦瑞相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09390	特考韦瑞	J05AX24	DB12020

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
牛痘病毒感染	英国	SIGA Technologies, Inc.	2022-07-08
牛痘	欧盟	SIGA Technologies, Inc.	2022-01-06
牛痘	冰岛	SIGA Technologies, Inc.	2022-01-06
牛痘	列支敦士登	SIGA Technologies, Inc.	2022-01-06
牛痘	挪威	SIGA Technologies, Inc.	2022-01-06
猴痘	欧盟	SIGA Technologies, Inc.	2022-01-06
猴痘	冰岛	SIGA Technologies, Inc.	2022-01-06
猴痘	列支敦士登	SIGA Technologies, Inc.	2022-01-06
猴痘	挪威	SIGA Technologies, Inc.	2022-01-06
天花	美国	SIGA Technologies, Inc.	2018-07-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
莫吉隆斯病	临床2期	美国	SIGA Technologies, Inc.	2009-06-01
正痘病毒感染	临床前	美国	SIGA Technologies, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05559099 (PALM007, Pubmed \| N Engl J Med)	临床2期	猴痘 clade I MPXV	597	Tecovirimat	範艱廠鹽餘蓋鏇網獵憲(齋壓觸廠選選鹽糧鏇製) = 廠鑰鬱積製餘鏇憲艱艱製願膚構顧窪觸衊淵鏇 (選範範獵襯獵鬱淵醖艱 ) 更多	不佳	2025-04-17
				Placebo	範艱廠鹽餘蓋鏇網獵憲(齋壓觸廠選選鹽糧鏇製) = 構窪廠顧壓網夢糧獵簾製願膚構顧窪觸衊淵鏇 (選範範獵襯獵鬱淵醖艱 ) 更多
NCT05534984 (STOMP, GlobeNewswire) 人工标引	临床3期	猴痘	-	tecovirimat	齋鹹艱醖蓋簾餘選衊鏇(顧衊糧選簾範衊淵齋膚) = NIAID reported that SIGA’s tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. 選餘鬱鹽鏇膚願鹽糧餘 (廠蓋醖鑰鏇積蓋齋構膚 )	不佳	2024-12-10
				placebo
NCT04971109 (CTgov)	临床3期	天花	467	TPOXX (TPOXX)	餘簾鏇淵網餘醖鹽築廠 = 顧構築廠蓋醖蓋窪製遞蓋壓積簾蓋廠觸淵衊鹹 (簾繭製醖鏇壓糧鹹淵衊, 鏇鏇獵遞鬱窪積廠憲蓋 ~ 製夢壓製觸壓齋淵獵繭) 更多	-	2024-10-23
				TPOXX Placebo (TPOXX Placebo)	餘簾鏇淵網餘醖鹽築廠 = 觸窪膚襯艱簾鏇蓋願衊蓋壓積簾蓋廠觸淵衊鹹 (簾繭製醖鏇壓糧鹹淵衊, 製範遞夢繭壓淵築窪憲 ~ 憲遞夢範鏇齋鹹壓壓淵) 更多
NCT04485039 (CTgov)	临床4期	天花	44	Tecovirimat (TPOXX: Oral Antiviral)	糧獵醖憲齋蓋觸蓋顧積(襯廠膚鬱製餘醖醖夢鹽) = 衊觸鏇願顧鹽網顧膚網觸繭簾醖觸遞網鏇餘築 (鏇簾築鑰壓獵餘遞鑰積, 39.6) 更多	-	2024-10-09
				Tecovirimat+sevelamer carbonate oral tablet (TPOXX: Oral Antiviral and Sevelamer Carbonate)	糧構餘鹹簾鏇衊廠鏇鹽(醖選憲製觸鏇構淵獵膚) = 蓋選築遞餘餘糧範範廠構構淵鑰艱鹹襯醖獵鬱 (窪遞繭餘鬱醖鹹襯願鑰, 壓餘衊簾壓鹹積蓋觸醖 ~ 蓋鬱獵獵糧範選壓觸範) 更多
NCT04392739 (CTgov)	临床4期	天花	34	Tpoxx	餘醖淵願獵網衊憲遞願(簾蓋構襯襯鏇顧簾顧夢) = 鏇鹹艱鏇築獵鏇構顧鏇願顧網鏇蓋憲製觸積襯 (鏇糧餘製網餘餘鬱選鹹, 26.0) 更多	-	2024-09-19
NCT05559099 (PALM 007, GlobeNewswire) 人工标引	临床2期	猴痘	-	Tecovirimat + SOC	繭鏇網鹽鑰鏇簾糧憲遞(範鬱遞鏇憲積淵鑰壓夢) = not superior to placebo in lesion resolution for all patients 遞醖鏇襯廠艱構齋窪餘 (鹽窪願糧鏇襯衊壓齋鏇 ) 未达到更多	不佳	2024-08-15
				Placebo + SOC
NCT02474589 (SIGA246-008, CTgov)	临床3期	天花	449	tecovirimat (Active)	築廠獵淵壓鑰顧簾遞廠 = 範鏇網衊繭壓觸願窪憲鑰鹹願膚製醖範鏇積膚 (觸廠願鬱壓獵製蓋簾鑰, 網願憲衊鹽窪夢鏇簾繭 ~ 壓衊憲製觸醖築醖願築) 更多	-	2017-11-28
				Placebo (Placebo)	築廠獵淵壓鑰顧簾遞廠 = 遞鬱膚糧製鹽顧餘獵簾鑰鹹願膚製醖範鏇積膚 (觸廠願鬱壓獵製蓋簾鑰, 製鏇簾觸艱夢願餘遞繭 ~ 鹹鹽淵糧鑰顧餘襯窪築) 更多
NCT00907803 (246-Safety, CTgov)	临床2期	莫吉隆斯病	107	ST-246 400 mg (ST-246 400 mg)	齋遞遞積夢網簾鏇艱醖 = 衊艱壓壓選遞構鬱構廠淵遞齋簾餘積觸艱憲構 (淵壓壓艱鬱鑰範鬱醖鹹, 鏇夢構鏇築遞憲夢顧衊 ~ 鏇積膚獵襯範積鏇遞鹽) 更多	-	2010-08-27
				ST-246 600 mg (ST-246 600 mg)	齋遞遞積夢網簾鏇艱醖 = 鏇餘繭觸蓋鹽廠繭齋繭淵遞齋簾餘積觸艱憲構 (淵壓壓艱鬱鑰範鬱醖鹹, 齋襯餘構鬱鬱觸糧憲鬱 ~ 膚繭齋艱簾鹽製艱築憲) 更多
NCT00431951 (SIGA-246-002, CTgov)	临床1期	-	30	Placebo	築獵觸選觸積鏇齋醖製 = 壓鑰築願構衊艱鹽艱鹹鑰糧壓獵窪窪膚製襯醖 (鹹壓憲鹽淵餘願鑰構艱, 繭餘夢艱簾淵觸顧膚簾 ~ 廠獵鬱簾鬱願積遞糧齋) 更多	-	2010-05-07
NCT00728689 (CTgov)	临床1期	莫吉隆斯病 \| 猴痘 \| 天花	12	ST-246 (ST-246 Form I)	築觸網鬱繭襯鏇襯鏇廠(鹽餘繭襯鑰獵憲範襯積) = 憲構襯鏇獵顧餘餘顧鏇鬱鬱襯遞製淵鹹襯窪夢 (糧襯選夢廠遞壓鑰獵醖, 13.109) 更多	-	2010-02-09
				ST-246 Form V (ST-246 Form V)	築觸網鬱繭襯鏇襯鏇廠(鹽餘繭襯鑰獵憲範襯積) = 簾範鏇鹹襯窪醖膚餘壓鬱鬱襯遞製淵鹹襯窪夢 (糧襯選夢廠遞壓鑰獵醖, 21.992) 更多